Login to Your Account

Financings NEWS
Study 'ready to go'

Apellis Pharmaceuticals Inc. extended its string of financings with a $60 million series E preferred stock round led by Sectoral Asset Management that included new investors Sofinnova, Vivo Capital, F-Prime Capital Partners, investment funds advised by Clough Capital Partners LP and Venbio Select. Existing investors Morningside Ventures, Cormorant Asset Management, Venbio Global Strategic Fund and Epidarex Capital also participated in the financing.

DUBLIN – A certain DNA endonuclease from Streptococcus pyogenes, Cas9, has gained enormous prominence as part of the revolutionary CRISPR-Cas9 genome editing system, but Hansa Medical AB is making waves with a different enzyme from the same bug.

Homology Medicines Inc. CEO Arthur Tzianabos told BioWorld that the new $83.5 million in series B money should let the firm "move our lead program all the way through a phase I/II proof-of-concept trial" while edging toward the clinic.

More Financings Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: